Beam Therapeutics Inc. (BEAM)

24,31 -1,39 (-5,41%) Alla chiusura: 04:00PM EDT

Beam Therapeutics Inc.

238 Main Street
9th Floor
Cambridge, MA 02142-1016
United States
857 327 8775
https://beamtx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 436

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. John M. Evans M.B.A.	CEO & Director	1,11M	9,03M	1978
Dr. Giuseppe Ciaramella Ph.D.	President	933,2k	1,27M	1969
Ms. Terry-Ann Burrell M.B.A.	CFO & Treasurer	711,15k	N/D	1977
Dr. Feng Zhang Ph.D.	Co-Founder	N/D	N/D	N/D
Dr. David R. Liu Ph.D.	Co-Founder	N/D	N/D	N/D
Dr. J. Keith Joung M.D., Ph.D.	Co-Founder	N/D	N/D	N/D
Dr. Nicole Gaudelli Ph.D.	Co-Founder	N/D	N/D	N/D
Dr. Alexis Komor Ph.D.	Co-Founder	N/D	N/D	N/D
Dr. Manmohan Singh Ph.D.	Chief Technology Officer	N/D	N/D	N/D
Dr. Gopi Shanker Ph.D.	Chief Scientific Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Beam Therapeutics Inc. al 1 aprile 2024 è 8. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 5; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.